Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

Calliditas Therapeutics (Calliditas), an Asahi Kasei company, announced today that new data was presented at the 62nd European Renal Association Congress (ERA Congress), which took place in Vienna, ...

Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Given the probability of trial success and current valuation, we rate the ATYR stock 'Hold' as risk and reward appear ...

In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Sibeprenlimab clinically reduces proteinuria in adults with immunoglobulin A nephropathy (IgAN), according to data from a prespecified analysis of the phase 3 VISIONARY trial presented during a ...

Researchers found that altering key enzymes involved in redox balance could disrupt the metabolism of Myc-driven lymphomas, ...

Otsuka's experimental therapy for a potentially life-threatening kidney disease more than halved severe levels of protein in the urine of patients, intensifying the battle for an effective new ...

Bound IgG were detected by a further 1-hour incubation ... The assay was then continued as a direct binding assay. HCMV UL94 protein production. The UL94 coding region was cloned in the expression ...